All In Biotech

Drug Trial Radar · NCT03766295

Masitinib Plus Gemcitabine in Pancreatic Cancer

A Prospective, Multicenter, Double-randomized, Double-blind, 2-parallel Groups, Phase 3 Study to Compare as First Line Therapy Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Gemcitabine in Combination With Placebo, in the Treatment of Patients With Non Resectable Locally Advanced or Metastatic Pancreatic Cancer

Last checked: Nov 19, 2026Latest source record: Dec 8, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 377 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

377

Actual

Start

Jul 2014

Primary completion

Dec 2020

Study completion Dec 2020

Sponsor

Lead sponsor
AB ScienceIndustry
Sponsor type
Industry
First posted
Dec 6, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective is to compare efficacy and safety of masitinib in combination with gemcitabine to placebo in combination with gemcitabine, in treatment of patients with locally advanced or metastatic pancreatic cancer and who have pain related to the disease.

Conditions

  • Locally Advanced or Metastatic Pancreatic Cancer

Interventions

  • MasitinibDrug

  • GemcitabineDrug

  • PlaceboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (median)Time frame: From day of randomization to death, assessed for a maximum of 60 months

Locations

9 sites in 8 countries. Site status is shown where the registry gives one.

  • Hospital AZ Sint-Jan

    Bruges, Belgium

  • Polyclinique de Limoges site CHENIEUX

    Limoges, France

  • Centre Hospitalier de Longjumeau

    Longjumeau, France

  • General University Hospital of Patras

    Pátrai, Greece

  • Sanjeevani CBCC USA Cancer Hospital

    Raipur, India

  • Omsk Clinical oncology dispensary Omsk

    Omsk, Russia

  • National Oncology Institute

    Bratislava, Slovakia

  • Institut Salah Azaiez de Cancerologie

    Bab Saadoun, Tunisia

  • Center of Surgical Innovations

    Kiev, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.